RESEARCH MONOGRAPH · KDC-MN-142

Atomoxetine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

79/100

The cleanest pharmacological tool for selective NET inhibition we have, and that selectivity is the whole point

Atomoxetine is the closest thing to a selective norepinephrine reuptake inhibitor in clinical use. Single-digit nanomolar Ki at NET, with selectivity over SERT and DAT of roughly 100-fold and 1000-fold respectively. Originally developed by Lilly as a putative antidepressant (the tomoxetine program in the 80s) that didnt show efficacy in depression but eventually found its indication in ADHD as Strattera in 2002.

The reason it works in ADHD is interesting and tells you something about ADHD pharmacology that the stimulants alone dont. Prefrontal cortex norepinephrine signaling (alpha2A receptor activation in particular) is important for executive function and working memory, and the prefrontal cortex has unusually high NET density and minimal DAT, which means NET inhibition selectively boosts prefrontal noradrenergic and dopaminergic tone (because NET also clears DA in prefrontal cortex) without producing the striatal dopamine surges that drive stimulant abuse liability.

What we like: this is the right tool when you want to interrogate prefrontal noradrenergic signaling without confounds from dopaminergic effects elsewhere. The pharmacology is clean. The clinical data set is large, the safety profile is well-characterized, and the lack of abuse liability differentiates it cleanly from methylphenidate and amphetamines mechanistically.

What we dont like: the time-to-effect is much slower than stimulants (weeks for full clinical effect rather than minutes), which has limited its clinical adoption despite the mechanistic cleanliness. The reason for the slow onset isnt fully understood; it may relate to gradual receptor adaptations downstream of sustained NET inhibition. There's also CYP2D6 dependence for clearance, which produces some pharmacokinetic variability across poor and rapid metabolizers.

Mechanism: well-mapped at the level of NET pharmacology. Downstream behavioral effects are partly mapped, with the alpha2A receptor in prefrontal cortex being a leading candidate node.

Sourcing: established generic, single-enantiomer (R-isomer), straightforward to characterize. Available as research-grade from major chemical suppliers with reliable quality.

Genuinely useful selective tool, underappreciated as a research compound for studying noradrenergic-specific effects on cognition without dopaminergic confounds. The slow-onset issue makes it less appealing as a stimulant alternative clinically but doesnt diminish its value for research.

Evidence: 90
Mechanism: 85
Reliability: 75
Safety: 78
Sourcing: 88
Value: 75
Signal: 65
Staying power: 75

Plain-language summary Intrigue 70 / 100

Atomoxetine, sold as Strattera, is a non-stimulant ADHD medication that selectively inhibits norepinephrine reuptake. It is the standard non-stimulant choice for patients who cannot tolerate or should not take stimulants. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Selective norepinephrine reuptake inhibitor

A selective NRI FDA-approved as Strattera for ADHD, the first non-stimulant FDA-approved for the indication.

Abstract

Atomoxetine (Strattera; CAS 83015-26-3; molecular formula C17H21NO; molecular weight 255.36) is a selective norepinephrine reuptake inhibitor (NRI) developed by Eli Lilly and approved by the FDA in 2002 for ADHD in children, adolescents, and adults. The compound is the first non-stimulant FDA-approved for ADHD. Mechanism is NET inhibition; the compound is essentially inactive at DAT and SERT. Pharmacokinetics: plasma half-life 5.2 hours in extensive metabolizers via CYP2D6, 21.6 hours in poor metabolizers; doses are titrated based on response and tolerability. Reported research dose ranges in the literature are described in the source publications. Schedule status: not scheduled (distinguishing it from amphetamine and methylphenidate ADHD therapies).

Mechanism of action

Selective norepinephrine reuptake inhibitor; minimal DAT/SERT activity.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Michelson D, et al. Atomoxetine in the treatment of children and adolescents with ADHD. Pediatrics 2001.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-142

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Atomoxetine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs